Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

YolTech Therapeutics

Company Type: Therapeutic development

Main focus: Developing potentially curative therapies using novel Cas and base editors and LNP delivery systems

Company stage: Clinical

Diseases: Metabolic diseases as well as various genetic disorders and infectious diseases

Genome-editing tool: CRISPR and base editing

Funding stage: Series A

Location: Minhang District, Shanghai, China

Website: YolTech (yoltx.com)

Pipeline: https://www.yoltx.com/pipeline/pipelines

Partners: Wimi Bio

YolTech Therapeutics is a biotechnology company that specialises in gene editing using novel CRISPR-Cas enzymes, base editors, and innovative lipid nanoparticle delivery systems to develop treatments for several diseases, including metabolic disorders and other rare genetic conditions. Their pipeline features ten investigative new therapies, with ongoing clinical trials for transthyretin amyloidosis and familial hypercholesterolemia.

Tags

HashtagYolTech Therapeutics

Company: YolTech Therapeutics
close
Search CRISPR Medicine